PureTech eyes a pivotal role in lung fibrosis treatment with LYT-100
US biotech PureTech Health (Nasdaq: PRTC) is positioning its lead candidate LYT-100 as a potential disruptor in the treatment of idiopathic pulmonary fibrosis (IPF), a rare lung condition long underserved by current therapies.
Early trial data suggest the drug may offer a more tolerable option for patients, with the possibility of matching or exceeding the efficacy of older standards of care, according to an analysis from GlobalData.
LYT-100, a deuterated form of pirfenidone, is being tested in Phase IIb studies and was spotlighted at the 2025 American Thoracic Society meeting. The data presented showed a potential to stabilize lung function over 26 weeks while maintaining a favorable safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze